pharmaphorum
MARCH 14, 2022
Cambridge, UK-based Coalesce, first formed in 2009 primarily as a contract services business, changed direction in 2014 to develop its own, in-house inhaler technologies.
Quality Matters
NOVEMBER 27, 2023
Amy Cadwallader (ABC): Drug shortages have reached an all-time high since 2014, and USP, along with several others, has been calling for more efforts to coordinate pharmaceutical supply chain resilience and reliability activities among federal agencies and non-governmental stakeholders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JULY 3, 2023
The Food and Drug Administration (FDA) approved an average of 43 drugs in 2014-18, compared to an average of 23 in the first decade of the century. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?
Quality Matters
JUNE 26, 2023
Complex generics: Are global regulators addressing the needs? The development of generic versions of innovator medicines is a global public health need. EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age. Geneva: World Health Organization; 2014. WHO Drug Inf.
Quality Matters
SEPTEMBER 15, 2023
For example, FDA established its Emerging Technology Program (ETP) in 2014 to facilitate emerging technologies like PCM and has already marked significant progress, Fisher said. Director, Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research (CDER), FDA.
Express Pharma
MARCH 12, 2025
The FDA has an established office in India overseeing the number of qualified manufacturers supplying generic medicines to the US. Inspection categorisation of Official Action Indicated (OAI) for Indian companies has decreased to 11 per cent in 2024 from 23 per cent in 2014, aligning with the global trend of 14 per cent in 2024.
Express Pharma
SEPTEMBER 11, 2023
This move unburdened the private pharma companies allowing them to concentrate and strengthen their base, and they succeeded in gaining a national as well as international market presence as “global generic medicine manufacturers.” Prices of brands are paradoxically high Pharma contributes 43.2
Expert insights. Personalized for you.
104 
Let's personalize your content